Aptahem

Aptahem Liabilities

The The Liabilities of Aptahem (APTA.SL) as of Oct 16, 2026 is 2.34 M SEK. In the previous year, The Liabilities was 9.00 M SEK — a change of -74.04% (lower).

Liabilities

2.34 MSEK

YoY

-74.04%

Last updated:

In 2024, Aptahem's total liabilities amounted to 2.34 M SEK, a -74.04% difference from the 9.00 M SEK total liabilities in the previous year.

The Aptahem Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2017
1.63 M SEK
Jan 1, 2018
5.75 M SEK
Jan 1, 2019
2.08 M SEK
Jan 1, 2020
4.45 M SEK
Jan 1, 2021
2.27 M SEK
Jan 1, 2022
9.45 M SEK
Jan 1, 2023
9.00 M SEK
Jan 1, 2024
2.34 M SEK
The Aptahem Liabilities history
YEARLiabilitiesYoY
2.34 MSEK-74.04%
9.00 MSEK-4.78%
9.45 MSEK+316.85%
2.27 MSEK-49.07%
4.45 MSEK+114.30%
2.08 MSEK-63.85%
5.75 MSEK+252.52%
1.63 MSEK+13.35%
1.44 MSEK+35.66%
1.06 MSEK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Aptahem Stock analysis

What does Aptahem do? Aptahem AB is a biotechnology company based in Malmö, Sweden, operating within the healthcare sector. The company focuses on developing drug candidates aimed at treating and preventing diseases caused by blood vessel blockages due to blood clots, including conditions such as deep vein thrombosis, stroke, and heart failure. Aptahem AB went public through an IPO on April 17, 2015, and is listed under the ticker APTA.SL with ISIN SE0022447173. The company's headquarters are located in Malmö, a city in the Skåne region of Sweden. While the source material mentions a founding year of 2014, this detail is not confirmed by the provided facts, so it is omitted. Aptahem AB's website, aptahem.com, serves as the primary online resource for information about the company's activities and developments. The company operates in the biotechnology industry, specializing in therapeutic solutions for cardiovascular and related conditions. As a publicly traded entity, Aptahem AB is subject to the regulatory requirements of the Swedish financial market. The firm's strategic focus lies in addressing unmet medical needs through innovative drug development, targeting conditions that significantly impact patient outcomes and healthcare systems. The company's operations are centered in Malmö, reflecting its commitment to contributing to the biotechnology ecosystem in southern Sweden. Aptahem is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Aptahem's Liabilities

Aptahem's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Aptahem's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Aptahem's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Aptahem's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Aptahem’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Aptahem stock

The Liabilities of Aptahem is 2.34 M SEK in 2024.

The Liabilities of Aptahem changed from 9.00 M SEK to 2.34 M SEK, representing a -74.04% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities Aptahem since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's SEK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's Aptahem historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Aptahem

All Key Metrics — Aptahem